comparemela.com

Latest Breaking News On - Silverstein foundation - Page 2 : comparemela.com

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

BETHESDA, Md., April 08, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Elio ambrosioNic johnsonMatthias alderGruntal coExchange commissionEuropean union horizonSwiss innovation agencyGain therapeutics incFordham universityMichaelj fox foundation for parkinson researchExchange commission onMerck coCompany annual report on formSilverstein foundation for parkinsonGene mackGain therapeutics

Gain Therapeutics Bolsters Management Team with the

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology.

Elio ambrosioMatthias alderNic johnsonExchange commission onCompany annual report on formSilverstein foundation for parkinsonEuropean union horizonMichaelj fox foundation for parkinson researchGain therapeutics incGruntal coSwiss innovation agencyExchange commissionFordham universityMerck coGene mackGain therapeutics

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M D , Ph D as Chief Medical Officer

BETHESDA, Md., April 01, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,.

Elio ambrosioNic johnsonJonas hannestadBristol myers squibbMatthias alderGain therapeutics incNeuropsychiatric instituteExchange commission onCompany annual report on formDuke school of medicineClinical development at alkahestUniversity of oviedoEuropean union horizonMichaelj fox foundation for parkinson researchCompensation committee of gain board directorsSilverstein foundation for parkinson

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M D , Ph D as

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation

Nic johnsonBristol myers squibbElio ambrosioJonas hannestadMatthias alderUniversity of messinaSilverstein foundation for parkinsonMichaelj fox foundation for parkinson researchClinical neuroscience research unitYale school of medicineCompensation committee of gain board directorsExchange commission onEuropean union horizonGain therapeutics incSwiss innovation agencyDuke school of medicine

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson s Disease -February 27, 2024 at 02:01 pm EST

BETHESDA, Md., Feb. 27, 2024 Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule.

Nic johnsonMatthias alderElio ambrosioBellberry human research ethics committeeExchange commissionGain therapeutics incCompany annual report on formMichaelj fox foundation for parkinson researchSilverstein foundation for parkinsonExchange commission onMultiple ascending doseSingle ascending doseChief executive officerSilverstein foundationGain therapeuticsSite directed enzyme enhancement therapy

vimarsana © 2020. All Rights Reserved.